• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Developmental and reproductive safety of Advax-CpG55.2 ™ adjuvanted COVID-19 and influenza vaccines in mice
Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.08.053. Online ahead of print.ABSTRACTSpikoGen® is a recombinant spike protein vaccine against COVID-19 that obtained marketing authorization in the Middle East on October 6th, 2021, becoming the first adjuvanted protein-based COVID-19 vaccine of its type to achieve approval. SpikoGen® vaccine utilizes a unique adjuvant Advax-CpG55.2, which comprises delta inulin and CpG55.2 oligonucleotide, a synthetic human toll-like receptor (TLR)-9 agonist. As part of a safety assessment, developmental and reproductive toxicity (DART) studies were undertaken in m...
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Isaac G Sakala Yoshikazu Honda-Okubo Nikolai Petrovsky Source Type: research

A deep-SIQRV epidemic model for COVID-19 to access the impact of prevention and control measures
This article proposes an artificial intelligence(AI) based intelligent prediction model called Deep-SIQRV(Susceptible-Infected-Quarantined-Recovered-Vaccinated) to simulate the spreading of COVID-19. While many models assume that vaccination provides lifetime protection, we focus on the impact of waning immunity caused by the conversion of vaccinated individuals back to susceptible ones. Unlike existing models, which assume that all coronavirus-infected individuals have the same infection rate, the proposed model considers the various infection rates to analyze transmission laws and trends. Next, we consider the influence ...
Source: Computational Biology and Chemistry - August 25, 2023 Category: Bioinformatics Authors: Aakansha Gupta Rahul Katarya Source Type: research

An Advax-CpG55.2 ™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.06.063. Online ahead of print.ABSTRACTTraditional protein-based vaccine approaches to COVID-19 were overshadowed by the new mRNA and adenoviral vector vaccine approaches which were first to receive marketing authorization. The current study tested for the first time in repurposed aged (median 15.4 years) cynomolgus macaques, a novel Advax-CpG55.2™ adjuvanted recombinant extracellular domain spike protein trimer antigen for immunogenicity, protection and safety. Nine animals received two intramuscular injections 10 days apart of recombinant spike prot...
Source: Vaccine - June 24, 2023 Category: Allergy & Immunology Authors: Yoshikazu Honda-Okubo Lei Li Greiciely Andr é King Ho Leong Elizabeth W Howerth Anne G Bebin-Blackwell Ted M Ross Nikolai Petrovsky Source Type: research

The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia
Acta Pharm. 2023 Jun 12;73(2):293-310. doi: 10.2478/acph-2023-0029. Print 2023 Jun 1.ABSTRACTWe aimed to identify whether a spontaneous reporting system (SRS) in Croatia could timely identify and confirm signals for COVID-19 vaccines. Post-marketing spontaneous reports of adverse drug reactions (ADRs) following COVID-19 immunisation reported to the Agency for Medicinal Products and Medical Devices of Croatia (HALMED) were extracted and analysed. 6624 cases reporting 30 655 ADRs following COVID-19 immunisation were received from 27th December 2020 to 31st December 2021. Available data in those cases were compared with data ...
Source: Acta Pharmaceutica - June 12, 2023 Category: Drugs & Pharmacology Authors: Barbara Kova čić Morana Pavi čić Nikica Miro šević Skvrce Sini ša Tomić Source Type: research

Pages: 1  2  3  4  5  6  7  8